Recent developments in l-asparaginase discovery and its potential as anticancer agent

Critical Reviews in Oncology/Hematology

Volumn 100, Issue , 2016, Pages 1-10

  Shrivastava, Abhinav ^a   Khan, Abdul Arif ^a,b   Khurshid, Mohsin ^b,c   Kalam, Mohd Abul ^b   Jain, Sudhir K ^d   Singhal, Pradeep K ^e  

^a Cancer Hospital and Research Institute   (India)

^b KING SAUD UNIVERSITY   (Saudi Arabia)

^c GOVERNMENT COLLEGE UNIVERSITY   (Pakistan)

^d VIKRAM UNIVERSITY   (India)

^e RANI DURGAVATI UNIVERSITY   (India)

Author keywords

Acute lymphoblastic leukaemia; Anticancer; Erwinase; Kidrolase; L Asparaginase; L Asparagine; PEG asparaginase

Indexed keywords

ACTINOMYCETES ASPARAGINASE; ALGAL ASPARAGINASE; ASPARAGINASE; ASPARAGINASE MACROGOL; ERWINIA ASPARAGINASE; FUNGAL ASPARAGINASE; PLANT ASPARAGINASE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; BLOOD CLOTTING DISORDER; COMPARATIVE STUDY; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG RESISTANCE; DRUG SYNTHESIS; ERYTHROCYTE; HUMAN; HYPERGLYCEMIA; LIVER TOXICITY; NONHUMAN; PANCREATITIS; REVIEW; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;

ANTINEOPLASTIC AGENTS; ASPARAGINASE; HUMANS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;

EID: 84960426299     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2015.01.002     Document Type: Review

References (104)

1. Adamson R.H., Fabro S. Antitumor activity and other biologic properties of L-asparaginase (NSC-109229) - a review. Cancer Chemother Rep 1968, 52(6):617-626.
2. Ahlke E., et al. Dose reduction of asparaginase under pharmacokinetic and pharmacodynamic control during induction therapy in children with acute lymphoblastic leukaemia. Br J Haematol 1997, 96(4):675-681.
3. Albertsen B.K., et al. Pharmacokinetics of Erwinia asparaginase after intravenous and intramuscular administration. Cancer Chemother Pharmacol 2001, 48(1):77-82.
4. Albertsen B.K., et al. Monitoring of Erwinia asparaginase therapy in childhood ALL in the Nordic countries. Br J Clin Pharmacol 2001, 52(4):433-437.
5. Albertsen B.K., et al. Antibody formation during intravenous and intramuscular therapy with Erwinia asparaginase. Med Pediatr Oncol 2002, 38(5):310-316.
6. Ali S.S., et al. Antineoplastic activity in L-asparaginase of Cladosporium cladosporiodies. Ind J Clin Biochem 1993, 8(1):68-70.
7. Appel I.M., et al. Lack of asparagine depletion in the cerebrospinal fluid after one intravenous dose of PEG-asparaginase: a window study at initial diagnosis of childhood ALL. Leukemia 2003, 17(11):2254-2256.
8. Arima K., et al. Production of extracellular L-asparaginases by microorganisms. Agri Biol Chem 1972, 36:356-361.
9. Armstrong J.K., et al. Antibody against poly(ethylene glycol) adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients. Cancer 2007, 110(1):103-111.
10. Asselin B.L. The three asparaginases. Comparative pharmacology and optimal use in childhood leukemia. Adv Exp Med Biol 1999, 457:621-629.
11. Asselin B.L., et al. Comparative pharmacokinetic studies of three asparaginase preparations. J Clin Oncol 1993, 11(9):1780-1786.
12. Ataullakhanov F.I., et al. Permeability of human erythrocytes to asparagines. Biokhimiya 1985, 50(10):1733-1737.
13. Athale U.H., Chan A.K. Thrombosis in children with acute lymphoblastic leukemia. Part II. Pathogenesis of thrombosis in children with acute lymphoblastic leukemia: effects of the disease and therapy. Thromb Res 2003, 111(4-5):199-212.
14. Avramis V.I., Panosyan E.H. Pharmacokinetic/pharmacodynamic relationships of asparaginase formulations: the past, the present and recommendations for the future. Clin Pharmacokinet 2005, 44(4):367-393.
15. Avramis V.I., Tiwari P.N. Asparaginase (native ASNase or pegylated ASNase) in the treatment of acute lymphoblastic leukemia. Int J Nanomedicine 2006, 1(3):241-254.
16. Avramis V.I., et al. A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study. Blood 2002, 99(6):1986-1994.
17. Berg H.V.D. Asparaginase revisited. Leuk Lymphoma 2010, 52(2):168-178.
18. Bodmer M., et al. Fatal liver failure in an adult patient with acute lymphoblastic leukemia following treatment with L-asparaginase. Digestion 2006, 74(1):28-32.
19. Boos J., et al. Monitoring of asparaginase activity and asparagine levels in children on different asparaginase preparations. Eur J Cancer 1996, 32A(9):1544-1550.
20. Broome J.D. Evidence that the L-asparaginase of guinea pig serum is responsible for its antilymphoma effects. II. Lymphoma 6C3HED cells cultured in a medium devoid of L-asparagine lose their susceptibility to the effects of guinea pig serum in vivo. J Exp Med 1963, 118:121-148.
21. Broome J.D. L-asparaginase: the evolution of a new tumor inhibitory agent. Trans N Y Acad Sci 1968, 30(5):690-704.
22. Carta de-Angeli L., et al. Effect of L-asparaginase from Aspergillus terreus on ascites sarcoma in the rat. Nature 1970, 225(5232):549-550.
23. Chabner B.A., Loo T.L. Enzyme therapy: L-asparaginase. Cancer chemotherapy and biotherapy, principle and practice (Vol. 2) 1996, Lippincott-Raven Pub. B. Chabner, D.L. Longo (Eds.).
24. Clementi A. La Désamidation Enzymatique De L'asparagine Chez Les Différentes Espéces Animales Et La Signification Physio Logique De Sa Presence Dans L'organisme. Arch Physiol Biochem 1922, 19(4):369-398.
25. Delage J.M., et al. l-Asparaginase and complement. Nature 1971, 233:485-486.
26. Dhevagi P., Poorani E. Isolation and characterization of L-asparaginase from marine actinomycetes. Ind J Biotechnol 2006, 5:514-520.
27. Distasio J.A., et al. Glutaminase-free asparaginase from vibrio succinogenes: an antilymphoma enzyme lacking hepatotoxicity. Int J Cancer 1982, 30(3):343-347.
28. Dolowy W.C., et al. Toxic and antineoplastic effects of L-asparaginase. Study of mice with lymphoma and normal monkeys and report on a child with leukemia. Cancer 1966, 19(12):1813-1819.
29. Douer D., et al. Pharmacodynamics and safety of intravenous pegaspargase during remission induction in adults aged 55 years or younger with newly diagnosed acute lymphoblastic leukemia. Blood 2007, 109(7):2744-2750.
30. Dox A.W. The intracellular enzymes of lower fungi, especially those in Penicillium camemberti. J Biol Chem 1909, 6:461-467.
31. Ebrahiminezhad A., et al. L-asparaginase production by moderate halophilic bacteria isolated from Maharloo Salt Lake. Indian J Microbiol 2012, 51(3):307-311.
32. Fromenty B., Pessayre D. Inhibition of mitochondrial beta-oxidation as a mechanism of hepatotoxicity. Pharmacol Ther 1995, 67(1):101-154.
33. Fromenty B., Pessayre D. Impaired mitochondrial function in microvesicular steatosis. Effects of drugs, ethanol, hormones and cytokines. J Hepatol 1997, 26(Suppl 2):43-53.
34. Fu C.H., Sakamoto K.M. PEG-asparaginase. Expert Opin Pharmacother 2007, 8(12):1977-1984.
35. Fullmer A., et al. Emerging therapy for the treatment of acute lymphoblastic leukemia. Expert Opin Emerg Drugs 2010, 15(1):1-11.
36. Gentili D., et al. L-asparagine depletion in plasma and cerebro-spinal fluid of children with acute lymphoblastic leukemia during subsequent exposures to Erwinia L-asparaginase. Ann Oncol 1996, 7(7):725-730.
37. Godfrin Y., Bertand Y. Oncology news 2006, 1(1):10-13.
38. Graham M.L. Pegaspargase: a review of clinical studies. Adv Drug Deliv Rev 2003, 55(10):1293-1302.
39. Hak L.J., et al. Asparaginase pharmacodynamics differ by formulation among children with newly diagnosed acute lymphoblastic leukemia. Leukemia 2004, 18(6):1072-1077.
40. Harris J.M., Chess R.B. Effect of pegylation on pharmaceuticals. Nat Rev Drug Discov 2003, 2(3):214-221.
41. Hernandez-Espinosa D., et al. L-asparaginase-induced antithrombin type I deficiency: implications for conformational diseases. Am J Pathol 2006, 169(1):142-153.
42. Holcenberg J.S., Teller D.C. Physical properties of antitumor glutaminase-asparaginase from Pseudomonas 7A. J Biol Chem 1976, 251(17):5375-5380.
43. Holle L.M. Pegaspargase: an alternative?. Ann Pharmacother 1997, 31(5):616-624.
44. Holleman A., et al. The expression of 70 apoptosis genes in relation to lineage, genetic subtype, cellular drug resistance, and outcome in childhood acute lymphoblastic leukemia. Blood 2006, 107(2):769-776.
45. Iiboshi Y., et al. L-asparaginase inhibits the rapamycin-targeted signaling pathway. Biochem Biophys Res Commun 1999, 260(2):534-539.
46. Iwamoto S., et al. Mesenchymal cells regulate the response of acute lymphoblastic leukemia cells to asparaginase. J Clin Invest 2007, 117(4):1049-1057.
47. Jacque N., Bouscary D. Targeting glutamine uptake in AML. Oncoscience 2014, 1(1):1-2.
48. Kaspers G.J., et al. Favorable prognosis of hyperdiploid common acute lymphoblastic leukemia may be explained by sensitivity to antimetabolites and other drugs: results of an in vitro study. Blood 1995, 85(3):751-756.
49. Keating M.J., et al. L-asparaginase and PEG asparaginase - past, present, and future. Leuk Lymphoma 1993, 10(Suppl):153-157.
50. Kelo E., et al. Depletion of L-asparagine supply and apoptosis of leukemia cells induced by human glycosylasparaginase. Leukemia 2009, 23(6):1167-1171.
51. Kidd J.G. Regression of transplanted lymphomas induced in vivo by means of normal guinea pig serum. I. Course of transplanted cancers of various kinds in mice and rats given guinea pig serum, horse serum, or rabbit serum. J Exp Med 1953, 98(6):565-582.
52. Killander D., et al. Hypersensitive reactions and antibody formation during L-asparaginase treatment of children and adults with acute leukemia. Cancer 1976, 37(1):220-228.
53. Kotzia G.A., et al. Tailoring structure-function properties of L-asparaginase: engineering resistance to trypsin cleavage. Biochem J 2007, 404(2):337-343.
54. Larson R.A., et al. Hypersensitivity reactions to L-asparaginase do not impact on the remission duration of adults with acute lymphoblastic leukemia. Leukemia 1998, 12(5):660-665.
55. Lee S.M., et al. L-asparaginase from Erwinia carotovora. An improved recovery and purification process using affinity chromatography. Appl Biochem Biotechnol 1989, 22(1):1-11.
56. Lough T.J., et al. L-asparaginase from developing seeds of Lupinus arboreus. Phytochemistry 1992, 31(5):1519-1527.
57. Loureiro C.B., et al. Purification and biochemical characterization of native and pegylated form of L-asparaginase from Aspergillus terreus and evaluation of Its ant proliferative activity. Adv Microbiol 2012, 2:138-145.
58. Mahajan R.V., et al. Efficient production of L-asparaginase from Bacillus licheniformis with low-glutaminse activity: Optimization, scale up and acrylamide degradation studies. Bioresour Technol 2012, 125C:11-16.
59. Mashburn L.T., Wriston J.C. Tumor inhibitory effect of L-asparaginase from Escherichia coli. Arch Biochem Biophys 1964, 105:450-452.
60. Miller H.K., et al. Amino acid levels following L-asparagine amidohydrolase (EC.3.5.1.1) therapy. Cancer Res 1969, 29(1):183-187.
61. Miniero R., et al. Hemostatic changes in children with acute lymphoblastic leukemia treated according to two different L-asparaginase schedules. Am J Pediatr Hematol Oncol 1986, 8(2):116-120.
62. Mitchell L.G., et al. Effect of disease and chemotherapy on hemostasis in children with acute lymphoid leukemia. Am J Pediatr Hematol Oncol 1994, 16(2):120-126.
63. Moola Z.B., et al. Erwinia chrysanthemi L-asparaginase: epitope mapping and production of antigenically modified enzymes. Biochem J 1994, 302(Pt 3):921-927.
64. Muller H.J., Boos J. Use of L-asparaginase in childhood ALL. Crit Rev Oncol Hematol 1998, 28(2):97-113.
65. Nowak-Gottl U., et al. Thrombotic events revisited in children with acute lymphoblastic leukemia: impact of concomitant Escherichia coli asparaginase/prednisone administration. Thromb Res 2001, 103(3):165-172.
66. Nowak-Gottl U., et al. Thromboembolic events in children with acute lymphoblastic leukemia (BFM protocols): prednisone versus dexamethasone administration. Blood 2003, 101(7):2529-2533.
67. Oza V.P., et al. Anticancer properties of highly purified L-asparaginase from Withania somnifera L. against acute lymphoblastic leukemia. Appl Biochem Biotechnol 2010, 160(6):1833-1840.
68. Panosyan E.H., et al. Asparaginase antibody and asparaginase activity in children with higher-risk acute lymphoblastic leukemia: Children's Cancer Group Study CCG-1961. J Pediatr Hematol Oncol 2004, 26(4):217-226.
69. Patil S., et al. Asparaginase in the management of adult acute lymphoblastic leukaemia: is it used appropriately?. Cancer Treat Rev 2011, 37(3):202-207.
70. Paul J.H. Isolation and characterization of a Chlamydomonas L-asparaginase. Biochem J 1982, 203(1):109-115.
71. Piatkowska-Jakubas B., et al. Use of L-asparaginase in acute lymphoblastic leukemia: recommendations of the Polish Adult Leukemia Group. Pol Arch Med Wewn 2008, 118(11):664-669.
72. Pieters R., et al. L-asparaginase treatment in acute lymphoblastic leukemia: a focus on Erwinia asparaginase. Cancer 2010, 117(2):238-249.
73. Pieters R., et al. L-asparaginase treatment in acute lymphoblastic leukemia: a focus on Erwinia asparaginase. Cancer 2011, 117(2):238-249.
74. Raja R.A., et al. Asparaginase-associated pancreatitis in children. Br J Haematol 2012, 159(1):18-27.
75. Riccardi R., et al. L-asparaginase pharmacokinetics and asparagine levels in cerebrospinal fluid of rhesus monkeys and humans. Cancer Res 1981, 41(11 Pt 1):4554-4558.
76. Rizzari C., et al. L-asparagine depletion and L-asparaginase activity in children with acute lymphoblastic leukemia receiving i.m. or i.v. Erwinia C. or E. coli L-asparaginase as first exposure. Ann Oncol 2000, 11(2):189-193.
77. Sahoo S., Hart J. Histopathological features of L-asparaginase-induced liver disease. Semin Liver Dis 2003, 23(3):295-299.
78. Salzer W., et al. Erwinia asparaginase in pediatric acute lymphoblastic leukemia. Expert Opin Biol Ther 2012, 12(10):1407-1414.
79. Scheetz R.W., et al. Purification and properties of an L-asparaginase from Fusarium tricinctum. Arch Biochem Biophys 1971, 142(1):184-189.
80. Schmalfuss K., Mothes K. Uber die fermentative Desamidierung durch Aspergillus niger. Bio- chemische Zeitschrift 1930, 221:134-153.
81. Schrey D., et al. Therapeutic drug monitoring of asparaginase in the ALL-BFM 2000 protocol between 2000 and 2007. Pediatr Blood Cancer 2010, 54(7):952-958.
82. Shrivastava A., et al. Biotechnological advancement in isolation of anti-neoplastic compounds from natural origin: a novel source of L-asparaginase. Acta Biomed 2010, 81(2):104-108.
83. Shrivastava A., et al. Kinetic studies of L-asparaginase from Penicillium digitatum. Prep Biochem Biotech 2012, 42(6):574-581.
84. Soares A.L., et al. Effects of polyethylene glycol attachment on physicochemical and biological stability of E. coli L-asparaginase. Int J Pharm 2002, 237(1-2):163-170.
85. Sodek L. Distribution and properties of a potassium-dependent Asparaginase isolated from developing seeds of Pisum sativum and other plants. Plant Physiol 1980, 65(1):22-26.
86. Stams W.A., et al. Asparagine synthetase expression is linked with L-asparaginase resistance in TEL-AML1-negative but not TEL-AML1-positive pediatric acute lymphoblastic leukemia. Blood 2005, 105(11):4223-4225.
87. Swain A.L., et al. Crystal structure of Escherichia coli L-asparaginase, an enzyme used in cancer therapy. Proc Natl Acad Sci U S A 1993, 90(4):1474-1478.
88. Thachil J. L-Asparaginase, nitric oxide and posterior reversible encephalopathy syndrome. Ann Hematol 2012.
89. Thomas X., et al. Therapeutic alternatives to native L-asparaginase in the treatment of adult acute lymphoblastic leukemia. Bull Cancer 2010, 97(9):1105-1117.
90. Verma N., et al. L-asparaginase: a promising chemotherapeutic agent. Crit Rev Biotechnol 2007, 27(1):45-62.
91. Veronese F.M. Peptide and protein PEGylation: a review of problems and solutions. Biomaterials 2001, 22(5):405-417.
92. Veronese F.M., Pasut G. PEGylation, successful approach to drug delivery. Drug Discov Today 2005, 10(21):1451-1458.
93. Vieira Pinheiro J.P., et al. Drug monitoring of low-dose PEG-asparaginase (Oncaspar) in children with relapsed acute lymphoblastic leukaemia. Br J Haematol 2001, 113(1):115-119.
94. Vieira Pinheiro J.P., et al. Serum asparaginase activities and asparagine concentrations in the cerebrospinal fluid after a single infusion of 2,500 IU/m(2) PEG asparaginase in children with ALL treated according to protocol COALL-06-97. Pediatr Blood Cancer 2006, 46(1):18-25.
95. Villa P., et al. L-asparaginase effects on inhibition of protein synthesis and lowering of the glutamine content in cultured rat hepatocytes. Toxicol Lett 1986, 32(3):235-241.
96. Wada H., et al. Antitumor enzyme: polyethylene glycol-modified asparaginase. Ann N Y Acad Sci 1990, 613:95-108.
97. Wang B., et al. Evaluation of immunologic crossreaction of antiasparaginase antibodies in acute lymphoblastic leukemia (ALL) and lymphoma patients. Leukemia 2003, 17(8):1583-1588.
98. Wenner K.A., et al. asparagine concentration in plasma after 2,500 IU/m(2) PEG-asparaginase i.v. in children with acute lymphoblastic leukemia. Klin Padiatr 2005, 217(6):321-326.
99. Williams D.A. A new mechanism of leukemia drug resistance?. N Engl J Med 2007, 357(1):77-78.
100. Wise D.R., Thompson C.B. glutamine addiction: a new therapeutic target in cancer. Trends Biochem Sci 2010, 35(8):427-433.
101. Woo M.H., et al. Hypersensitivity or development of antibodies to asparaginase does not impact treatment outcome of childhood acute lymphoblastic leukemia. J Clin Oncol 2000, 18(7):1525-1532.
102. Wriston J.C., Yellin T.O. L-asparaginase: a review. Adv Enzymol Relat Areas Mol Biol 1973, 39:185-248.
103. Wu M.C., et al. Mechanism of sensitivity of cultured pancreatic carcinoma to asparaginase. Int J Cancer 1978, 22(6):728-733.
104. Zeidan A., et al. Pegasparaginase: where do we stand?. Expert Opin Biol Ther 2009, 9(1):111-119.